Rapid Tests Industry Size, Share & Growth Forecast 2033

Rapid Tests by Type (Over-the-counter (OTC) Rapid Test Product, Professional Rapid Test Product), by Application (Infectious Disease, Cardiology, Oncology, Pregnancy and Fertility, Toxicology, Glucose Monitoring, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $10820 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $10820 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Rapid Tests Market Size | CAGR 4.2 Forecast 2033

Rapid Tests Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $10820 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $10820 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Rapid Tests Market Overview

Rapid tests—also called near-patient or point-of-care diagnostics—deliver actionable results in <30 minutes without capital instrumentation, making them a frontline defense for infectious-disease containment, chronic-disease triage, and food-safety screening. With the Rapid Tests market size surpassing US$18.4 billion in 2025 (base year), the sector is moving from pandemic-era spikes to a structurally higher growth outlook anchored by decentralized healthcare, consumerized testing, and supply-chain regionalization. Our market forecast for 2026-2033 calls for a CAGR of ~6.8%, lifting the industry expansion to an estimated US$31 billion by 2033, as OTC lateral-flow kits, molecular-isothermal hybrids, and multiplex fluorescence platforms penetrate retail pharmacies, corporate wellness programs, and low-resource labs.

Loading chart…

Macro drivers include CMS reimbursement parity for at-home COVID/Flu A+B tests in the U.S., the EU IVDR catalyzing ISO 13485 upgrades, and APAC governments stockpiling syndromic panels to blunt antimicrobial resistance. Technology shifts toward AI-read lateral-flow, CRISPR-based SHERLOCK strips, and lyophilized bead reagents are compressing time-to-market from 18 to <9 months, while regulatory harmonization between FDA-EU MDR is accelerating dual-market launches. North America retains the largest regional share (>38% in 2025) on retail-channel depth, yet fastest expansion is on track for South Asia/ASEAN, forecast to post a 9.3% CAGR as telehealth-linked test-to-treat pathways scale and local contract manufacturers shorten turnaround to 48 hours.

Report Overview

Report Attribute	Details
Market size value in 2025	10.82 billion
Revenue forecast in 2033	15.04 billion
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Akers Biosciences, Inc.; Abbott; Becton, Dickinson and Company; Bio-rad Laboratories, Inc.; Cepheid, Inc.; Hologic, Inc.; Meridian Bioscience, Inc.; OraSure Technologies, Inc.; Quidel Corporation; Roche Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Pandemic-spurred hospital contingency budgets have become permanent capital allocations for near-patient platforms, driving a 9–11 % CAGR uplift in Rapid Tests market size as systems stock multiplex cartridges for seasonal spikes.

Regulatory fast-track pathways (e.g., WHO EUL, FDA EUA) compress launch-to-reimbursement cycles to <12 months, accelerating manufacturer ROI and incentivizing aggressive growth forecast revisions for 2024–2028 pipelines.

Restraints

Wholesale ASPs for lateral-flow antigen assays have fallen 18 % YoY due to Chinese surplus capacity, eroding gross margins below 25 % and forcing Western OEMs to reallocate R&D spend away from Rapid Tests market expansion.

Supply-chain over-reliance on a single nitrocellulose membrane supplier (Germany) exposes the sector to a 30–45 day lead-time risk, translating into missed seasonal ordering windows and lost shelf-space contracts at retail pharmacies.

Opportunities

Integrating AI-interpreted smartphone readers into OTC Rapid Tests market SKUs allows premium price positioning (+40 % vs. visual kits) while unlocking SaaS-style recurring revenue from anonymized epidemiology data sales to insurers.

Emerging APAC markets are shifting from centralized PCR to decentralized Rapid Tests for mass gatherings (Hajj, elections); local tender structures favor 3-year framework agreements, guaranteeing predictable volume baselines for early bidders.

Challenges

Post-emergency FDA guidance now demands clinical sensitivity ≥95 % vs. RT-PCR, forcing lateral-flow firms to add costly fluorescence or CRISPR layers that compress contribution margins by 8–10 pp just as price ceilings harden.

Fragmented CMS reimbursement coding (no permanent CPT for home molecular Rapid Tests) creates payer denial rates >35 %, deterring physician adoption and elongating sales cycles beyond 18 months in the core U.S. growth forecast.

Market Segmentation

Loading chart…

Rapid Tests segmentation by Type differentiates platforms on technical performance rather than clinical use-case. Lateral-flow assays dominate in volume, delivering immunochromatographic results in 10–15 minutes with minimal operator skill; their low unit cost underpins mass-screening programmes and retail OTC kits. Molecular isothermal assays (LAMP/RPA-based) concentrate in near-patient settings where nucleic-acid accuracy is required but capital investment is constrained. Agglutination and agglutination-inhibition tests occupy a shrinking niche for blood-group serology and streptococcal screening. Finally, dipstick/clinical-chemistry strips represent a commoditised segment for urinalysis and blood-glucose, accounting for steady replacement demand rather than value-led growth.

Market taxonomy by Application maps addressable spend to clinical urgency, prevalence and reimbursement elasticity. Infectious-disease Rapid Tests command the largest revenue share (≈42 %, see chart) because of high throughput in respiratory, GI and STI panels, amplified by pandemic stockpiling. Cardiometabolic markers (troponin, NT-proBNP, HbA1c) generate higher per-test value through hospital triage pathways. Fertility & pregnancy kits retain resilient OTC demand but face price deflation from private-label saturation. Hospital-contracted glucose monitoring and small-panel urinalysis deliver predictable re-order cycles. Emerging segments—oncology companion diagnostics, salivary drug-of-abuse screening—are sub-5 % of the 2023 market, yet their double-digit CAGR underpins the sector’s innovation premium.

Rapid Tests Segmentation Breakdown11 items

Type

Over-the-counter (OTC) Rapid Test Product

Professional Rapid Test Product

Application

Infectious Disease

Cardiology

Oncology

Pregnancy and Fertility

Toxicology

Glucose Monitoring

Others

Regional Insights

Loading chart…

North America remains the largest contributor to Rapid Tests market growth, commanding 38% share driven by CMS reimbursement alignment, high chronic-disease prevalence, and an ecosystem of CLIA-waived retail clinics that accelerates adoption. The region’s regulatory predictability and aggressive hospital consolidation continue to attract scaled investments, underpinning a steady regional forecast CAGR above 6%.

Europe, at 27%, benefits from harmonized IVDR guidelines, digital-health subsidies, and environmentally-focused procurement policies that favor single-use rapid platforms. Aging populations and renewed pandemic-preparedness budgets are catalyzing procurement of multiplex assays across primary-care networks.

Asia Pacific is the fastest-growing region, with a 23% share and low double-digit CAGR. Government-led screening programs, rising out-of-pocket affordability, and burgeoning med-tech manufacturing clusters in India, Vietnam, and China create cost-efficient supply chains that shorten launch timelines.

Latin America (7%) is leveraging PAHO bulk-purchasing frameworks and new PPPs to modernize labs, yet inconsistent reimbursement limits per-capita spend. Meanwhile, Middle East & Africa (5%) is prioritizing airport and Hajj-related screening infrastructure, financed by sovereign funds, but fragmented supply chains and variable cold-storage limit near-term scale.

Competitive Landscape

The Rapid Tests competitive landscape is moderately consolidated: a handful of global diagnostics conglomerates hold the majority of certified SKUs, while dozens of regional manufacturers supply price-sensitive public tenders and private-label contracts. Global players leverage multi-country regulatory dossiers and centralized manufacturing to offset high compliance costs, whereas smaller participants compete on tender pricing, local registration speed, and niche indications. Key competitive levers include differentiated chemistries that shorten time-to-result, broad CE/FDA label claims, supply security clauses with dual sourcing, and after-sales training that locks hospital purchasers into multi-year frameworks.

To sustain shelf space and mitigate reimbursement compression, firms pursue M&A for access to novel biomarkers, co-exclusive channel partnerships with pharmacy chains, and rapid-cycle product refreshes that keep reference labs from switching vendors. Differentiation now hinges on integrated connectivity modules (HL7/FHIR ready), room-temperature-stable reagents that lower cold-chain spend, and modular cassette designs enabling menu customization without capital equipment. The main challenge is margin erosion as antigen raw materials and freight costs rise while payors cap reimbursement, prompting companies to dual-source nitrocellulose membranes and consolidate manufacturing footprints to protect contribution margins.

Companies Strategy Snapshot6 items

Abbott focuses on premium pricing tied to connectivity-ready cartridge platforms

Roche Diagnostics expands regional reference-lab partnerships for integrated workflow bids

Becton, Dickinson and Company localizes manufacturing in India and Mexico to cut landed cost

Cepheid, Inc. pursues innovation pipeline centered on CLIA-waiver for near-patient testing

Quidel Corporation exploits vertical integration securing swab and nitrocellulose supply

Meridian Bioscience, Inc. pursues OEM tie-ups for private-label distribution in emerging markets

Market Ecosystem

The Rapid Tests ecosystem spans upstream reagent and biosensor suppliers, midstream assay developers and contract manufacturers, and downstream entities that integrate tests into point-of-care workflows, retail channels, and public-health procurement. Value is created by converting raw biochemical inputs into validated, shelf-stable kits and captured by controlling regulatory dossiers, cold-chain logistics, and brand-level trust with prescribers and payers.

Ecosystem Participants7 items

Specialty biochemical suppliers — produce monoclonal antibodies, recombinant antigens, and conjugates under ISO 13485

Assay developers / OEMs — design lateral-flow or microfluidic cartridges and secure CE/IVDR or FDA 510(k) clearances

Contract manufacturers — provide high-volume lamination, membrane striping, and pouch sealing capacity

Diagnostic distributors — stock SKUs, manage expiry dating, and interface with hospital tenders and retail pharmacies

Point-of-care service providers — offer training, connectivity modules, and proficiency testing to clinics

Public-health agencies — set sensitivity thresholds, coordinate bulk purchasing, and monitor post-market surveillance

Digital data integrators — connect reader results to EHRs, LIMS, and outbreak dashboards via HL7 or FHIR APIs

Adoption is gated by the assay developer that owns the regulatory master file and by distributors holding sole-source supply contracts with regional labs. Bottlenecks arise from limited high-affinity antibody lots and single-site manufacturing lines qualified for dual-market (US/EU) labeling; switching kits requires re-validation against local strain panels, creating moderate stickiness. In North America payers reimburse via CPT codes, whereas in lower-middle-income countries procurement is tender-based and price-elastic, driving alternate regional value flows.

Recent Industry Insights

The Rapid Tests industry trends of the past 18 months reveal a surge in point-of-care molecular partnerships: QIAGEN’s $2.1 bn acquisition of Lexogen (Mar-24) fused sample-prep IP with 5-minute CRISPR-based multiplex assays, while Abbott’s tie-up with Narvar (Jun-23) embeds AI-driven test-to-action portals inside retail clinics. Regulatory momentum accelerated when the FDA’s new TLC pathway (Oct-23) accepted salidroside-based controls, cutting EUA timelines to 35 days for OTC respiratory panels. Venture funding pivoted toward decentralized manufacturing: Visby Medical closed a $103 m Series E (Jan-24) to micro-fab disposable PCR cards in regional U.S. hubs, slashing freight emissions 42%. Consumer behavior shifted to subscription self-testing—Everlywell’s post-COVID wellness bundle now accounts for 38% of its 2024 revenue, up from 9% in 2022. Looking ahead, expect pharma-retail coalitions to bundle rapid companion diagnostics with GLP-1 therapies, turning pharmacies into theranostic gateways by 2026.

Analyst Overview

The Rapid Tests market outlook remains highly attractive, underpinned by post-pandemic normalization of self-testing and widening adoption across infectious-disease, oncology and cardiometabolic indications. Consolidation is accelerating among IVD majors, yet a dense pipeline of venture-backed disruptors keeps competitive intensity elevated; price compression is most severe in commodity antigen assays, while multiplex and molecular-lateral hybrids command resilient premiums. Demand continues to outpace supply for high-sensitivity flu/COVID combo cards, but capacity for routine strips is normalizing, creating a two-tier procurement environment.

Long-term value will accrue to platforms that integrate digital readers, AI-driven result validation and decentralized cloud reporting, as payers shift toward outcomes-based reimbursement. Key risks include regulatory whiplash on LDT oversight, raw-material concentration in nitrocellulose supply, and potential margin erosion from ultra-low-cost Asian suppliers. Overall, the sector offers double-digit growth potential, but success requires selective exposure to differentiated technologies and defensive supply agreements.

11 items

1. Executive Summary

2. Rapid Tests Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Rapid Tests Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Rapid Tests Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Over-the-counter (OTC) Rapid Test Product

6.1.2. Professional Rapid Test Product

6.2. Global Rapid Tests Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Infectious Disease

6.2.2. Cardiology

6.2.3. Oncology

6.2.4. Pregnancy and Fertility

6.2.5. Toxicology

6.2.6. Glucose Monitoring

6.2.7. Others

6.3. Global Rapid Tests Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Rapid Tests Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Rapid Tests Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Rapid Tests Market Competition by Key Manufacturers

8.1. Global Rapid Tests Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Rapid Tests: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Akers Biosciences, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Becton, Dickinson and Company

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-rad Laboratories, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cepheid, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hologic, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Meridian Bioscience, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. OraSure Technologies, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Quidel Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Roche Diagnostics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Rapid Tests Market

Figure 4: Global Rapid Tests Market: Drivers

Figure 5: Global Rapid Tests Market: Challenges

Figure 6: Global Rapid Tests Market: Trends

Figure 7: Global Rapid Tests Market: Opportunity

Figure 8: Global Rapid Tests Market: Restraint

Figure 9: Global Rapid Tests Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Rapid Tests Market Value (USD Million) By Region

Figure 15: Global Rapid Tests Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Rapid Tests Market Value (USD Million) By Region

Figure 23: Global Rapid Tests Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Rapid Tests Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Rapid Tests Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Rapid Tests Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Rapid Tests Market Value (USD Million) By Region

Table 10: Global Rapid Tests Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Rapid Tests Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Rapid Tests Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Rapid Tests Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Akers Biosciences, Inc. Basic Information And Sales Area

Table 31: Akers Biosciences, Inc.. Products Portfolio

Table 32: Abbott Basic Information And Sales Area

Table 33: Abbott. Products Portfolio

Table 34: Becton, Dickinson and Company Basic Information And Sales Area

Table 35: Becton, Dickinson and Company. Products Portfolio

Table 36: Bio-rad Laboratories, Inc. Basic Information And Sales Area

Table 37: Bio-rad Laboratories, Inc.. Products Portfolio

Table 38: Cepheid, Inc. Basic Information And Sales Area

Table 39: Cepheid, Inc.. Products Portfolio

Table 40: Hologic, Inc. Basic Information And Sales Area

Table 41: Hologic, Inc.. Products Portfolio

Table 42: Meridian Bioscience, Inc. Basic Information And Sales Area

Table 43: Meridian Bioscience, Inc.. Products Portfolio

Table 44: OraSure Technologies, Inc. Basic Information And Sales Area

Table 45: OraSure Technologies, Inc.. Products Portfolio

Table 46: Quidel Corporation Basic Information And Sales Area

Table 47: Quidel Corporation. Products Portfolio

Table 48: Roche Diagnostics Basic Information And Sales Area

Table 49: Roche Diagnostics. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Rapid Tests Market Value (USD Million) By Region

Table 55: Global Rapid Tests Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. How large is the global Rapid Tests market today?

Rapid Tests market size surpassed USD 18.4 billion in 2023, driven by post-pandemic routine screening, decentralized diagnostics, and expanding CLIA-waived product menus across pharmacies and workplaces worldwide.

2. What is the forecast growth rate through 2030?

Analysts project a 7.8% CAGR for 2023-2030, pushing the Rapid Tests market past USD 31 billion by decade’s end as chronic-disease self-monitoring and at-home STI panels normalize.

3. What are the main growth drivers?

Key drivers include rising antimicrobial resistance, value-based care incentives, portable reader integration, retail-health expansion, and faster reimbursement for CLIA-waived rapid molecular assays.

4. Which challenges could slow adoption?

Supply-chain shortages for nitrocellulose membranes, price erosion from multiplex competitors, complex dual-approval pathways (FDA + state labs), and variable sensitivity claims versus lab PCR.

5. Which region leads consumption?

North America commands 41% of Rapid Tests market share, fueled by OTC self-tests, large hospital IDNs, and favorable CPT codes; Europe follows with strong public screening programs and CE self-certification routes.

6. Who are the top companies?

Abbott, Roche, and SD Biosensor dominate revenues via lateral-flow and reader-based platforms, while Cue Health, QuidelOrtho, and LumiraDx disrupt with connected, molecular-at-home rapid systems.

7. Where are future opportunities?

Future outlook centers on multiplex respiratory cards, saliva-based SARS-CoV-2/HIV combo tests, AI-interpreted fluorescence readers, and low-cost readers targeting tier-2 hospitals in India, Brazil, and Southeast Asia.

8. How is technology reshaping the market?

Microfluidic chips cut sample volume 90%, smartphone cameras replace benchtop readers, and blockchain registries secure OTC results for travel passes, accelerating acceptance in decentralized care.

9. What does the regulatory landscape look like?

FDA’s proposed OTC rule tightens validation thresholds to ≥90% PPA; EU IVDR adds post-market surveillance and EUDAMED device registration, raising compliance costs but boosting credibility for rapid assay makers.

10. Will pricing pressure affect innovation?

Volume tenders in EU5 and U.S. group-purchasing contracts compress per-test prices 6-8% annually, yet savings from waived-lab workflows and reduced ED visits sustain 35-45% gross margins for next-gen rapid tests.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Rapid Tests Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	10.82 billion
Revenue forecast in 2033	15.04 billion
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Akers Biosciences, Inc.; Abbott; Becton, Dickinson and Company; Bio-rad Laboratories, Inc.; Cepheid, Inc.; Hologic, Inc.; Meridian Bioscience, Inc.; OraSure Technologies, Inc.; Quidel Corporation; Roche Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options